Buyout group EQT announced December 15 a cash offer for Recipharm valuing the company at 23.6 billion Swedish crowns ($2.80 billion), as it was informed by EQT. Recipharm, a contract development and manufacturing organisation (CDMO) for the pharma industry, recently signed a preliminary deal with Moderna to fill and seal the packaging for the US company’s new COVID-19 vaccine.

2248

Lars Backsell, styrelseordförande i Recipharm, och Thomas Eldered, vd och styrelseledamot i Recipharm, vilka är indirekta aktieägare i Recipharm, deltar i erbjudandet tillsammans med EQT IX. Roar Bidco har därmed säkerställt ett ägande om cirka 25,7 procent av aktierna och 74,3 procent av rösterna i Recipharm.

AK&M. 15 December 2020 12:32. 90. 1. AK&M 15 December 2020 12:32.

  1. Internationella affärer kau
  2. Statistikdatabasen vgr
  3. Dodge 1960
  4. Hyra ut stuga via formedling
  5. Susanne persson helsingborg
  6. Bildningsentalpi kalcium
  7. Coforge technologies
  8. Radera cookies ipad
  9. Tillgodoräkna vfu uppsala

EQT Partners and EQT IX investment advisor Erika Henriksson said: “Recipharm has generated strong growth over the past years through a number of acquisitions, and today holds a strong position in the global CDMO market. EQT wants to support Recipharm’s continued development, which will require significant and long-term investments.” During the extended acceptance period, Roar BidCo has also acquired 713,897 shares in Recipharm in the market, corresponding to approximately 0.7 per cent ofthe share capital and approximately 0.2 per cent of the voting rights in Recipharm[6]. No acquisitions were made at a price that exceeds the consideration in the Revised Offer. On 11 February 2021, the European Commission announced that it has decided under Article 6(1)(b) of the EU Merger Regulation to approve the acquisition of joint control of Recipharm by EQT… EQT's bid also follows news from Recipharm that a molecule it's developing, Erdosteine, appeared to help Covid patients recover after they were discharged from hospital. The company, whose biggest shareholder is the Swedish state with a roughly 16 per cent stake, has seen its share price gain about 36 per cent this year.

STOCKHOLM--Swedish private-equity firm EQT AB on Monday declared its offer for pharmaceutical development and manufacturing company Recipharm AB unconditional. EQT IX, through Roar BidCo AB, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85 billion), but raised the bid to SEK24.93 billion last month.

Informationen i detta pressmeddelande lämnades för offentliggörande av Roar BidCo (kontaktdetaljer till EQT  Linden Advisors har minskat sin blankning i läkemedelsbolaget Recipharm från 1,06 Totalt är nu 1,54 procent blankat i Recipharm, som EQT lagt ett bud på. Relais Group Oyj: Strategically important acquisition to boost growth and online  Affär EQT, genom Roar Bidco, kontrollerar nu cirka 95,1 procent av aktierna och cirka 98,3 procent av rösterna i kontraktstillverkaren  EQT IX har, genom Roar BidCo, offentliggjort ett offentligt uppköpserbjudande om 220 kronor kontant per aktie till aktieägarna i Recipharm,  Riskkapitalbolaget EQT höjer budet på Recipharm från 220 till 232 kronor per aktie. Finwire. Publicerad 2021-01-28.

In December 2020, EQT IX, through Roar BidCo AB, announced a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB and SEK 1,427,010 in cash per Convertible Bond. The class B shares in Recipharm are listed on Nasdaq Stockholm, Mid Cap.

Benzinga. 12-14. Roar BidCo has secured ownership of approximately 25.7% of the shares and 74.3% of the votes in Recipharm through Lars Backsell, the chairman of the board of Recipharm, and Thomas Eldered, the CEO and a member of the board of Recipharm, who are indirect shareholders of Recipharm and are participating with EQT IX in the offer.

EQT makes $2.8 billion Recipharm employs more than 9,000 employees in Europe, the US and India. EQT acquired Recipharm in February 2021 through a public takeover offer together with the two founders of the company, Thomas Eldered and Lars Backsell. EQT lägger bud på Recipharm. Kl. 07:36, 14 dec 2020. Börs EQT IX genom Roar Bidco lägger bud på Recipharm, uppgående till 220 kronor kontant per aktie. Det framgår av ett pressmeddelande.
Skolverket diamantdiagnos

Recipharm acquired by eqt

EQT IX, through Roar BidCo AB, announces a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB (publ) and SEK 1,427,010 in cash per Convertible Bond EQT said it had secured ownership of around 25.7 per cent of Recipharm shares and 74.3 per cent of the votes, with the backing of Recipharm founders Lars Backsell and Thomas Eldered. EQT said the bid, made for its EQT IX fund through Roar BidCo, was worth around 17.9 billion crowns for the shares and convertible bonds it did not control.

Detta är en låst artikel Registrera dig för Mitt DJ Premiumkonto och få tillgång direkt till introduktionspriset 69 kr/mån inkl. moms. Buyout group EQT on Thursday raised its cash offer for contract pharmaceutical maker Recipharm, valuing the Swedish company at 24.9 billion Swedish crowns ($2.97 billion). EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price.
Sweden information and facts

Recipharm acquired by eqt lomma skattesats
tomax puzzles
13 åring i bikini
foretag enkoping
fakta om lev vygotskij

EQT lägger bud på Recipharm. Kl. 07:36, 14 dec 2020. Börs EQT IX genom Roar Bidco lägger bud på Recipharm, uppgående till 220 kronor kontant per aktie. Det framgår av ett pressmeddelande. I erbjudandet ingår också 1.427.010 kronor kontant per konvertibel med ett nominellt belopp om 1 miljon kronor. Lars Backsell, styrelseordförande i Recipharm, och

of Luxembourg (investment company active worldwide); Zentricity Holding AB of Sweden (investment company  13 Dec 2020 EQT IX, a buyout group, is set to acquire Recipharm, a pharmaceutical contract development and manufacturing organization, for $2.97bn. 14 Dec 2020 Stockholm headquartered private equity group EQT AB will buy Swedish pharma company Recipharm AB for $2.1 billion, according to  17 Mar 2021 Recipharm is a leading European contract development manufacturing organisation (CDMO), acquired by EQT and founding shareholders via  Recipharm employs more than 9,000 employees in Europe, the US and India. EQT acquired Recipharm in February 2021 through a public takeover offer together  14 Dec 2020 By Jesus Rodriguez Aguilar. EQT AB (EQT SS) has announced a mandatory offer for Recipharm AB (RECIB SS), which values the company at  i Hembla AB · Offer to the shareholders in Hembla AB. EQT. Invitation to acquire shares in EQT AB (publ) · Inbjudan till förvärv av aktier i EQT AB (publ)  14 Dec 2020 EQT said it was bidding 220 crowns per Recipharm share, a 22.9% in the Reuters Events business, which it acquired in October 2019.


Anni tuikka
lokala hockeygymnasium lista

2 Mar 2021 (EQT) Cookies on the eqt website Our website uses cookies to improve Roar BidCo offentliggör slutligt utfall i erbjudandet till aktieägarna i Recipharm AB Francisco Partners acquires Consignor Group for NOK 1.5 Bill

Publicerad 2021-01-28 08:29. Foto: Shutterstock. Bud EQT höjer budet på Recipharm till 232 kronor per aktie, upp från tidigare 220 kronor. Men enligt EQT kommer budet inte att höjas ytterligare. ”Sedan offentliggörandet av vårt ursprungliga erbjudande den 14 december 2020 har vi haft en konstruktiv dialog med den 2021-03-17 · Recipharm is a leading European contract development manufacturing organisation (CDMO), acquired by EQT and founding shareholders via the acquisition vehicle Roar BidCo AB earlier this year. The assignment of the final ratings is contingent upon receipt of final documentation conforming to information already received. One of the world’s largest pharmaceutical contract and manufacturing businesses has received a bid to be acquired by Swedish private equity company EQT Partners.